2018 Annual Meeting of the American Association for the Study of Liver Diseases*

Expert faculty members summarize key viral hepatitis studies from this important annual conference. Use these slides to review data on newer HCV regimens, the HCV continuum of care, posttreatment HCV outcomes, HCV D+R- transplantation, NA cessation in chronic hepatitis B, and investigational HBV/HDV therapeutics.

Paul Y. Kwo, MD Nancy Reau, MD Released: November 28, 2018

Listen to downloadable audio from a live Webinar by Jordan J. Feld, MD, MPH, in which the clinical impact of new viral hepatitis data reported at the San Francisco meeting is discussed.

Jordan J. Feld, MD, MPH Released: November 28, 2018

Here’s my take on how data presented in San Francisco shed light on where we can improve HBV care.

Norah Terrault, MD, MPH Released: December 3, 2018

Expert faculty summarize key NAFLD/NASH studies from this important annual conference. Use these slides to review data on noninvasive screening, clinical outcomes, emerging treatments.

Ira M. Jacobson, MD Philip N. Newsome, PhD, FRCPE Released: December 3, 2018

Listen to downloadable audio from a live Webinar by Zobair M. Younossi, MD, MPH, FACP, FACG, AGAF, in which the clinical impact of new NAFLD/NASH data reported at the San Francisco meeting are discussed.

Zobair M. Younossi, MD, MPH, FACP, FACG, AGAF, FAASLD Released: November 27, 2018

Here’s my take on where we are heading in assessing NASH endpoints in clinical trials.

Vlad Ratziu, MD, PhD Released: December 13, 2018